Advertisement
Advertisement
U.S. Markets open in 7 hrs 1 min
Advertisement
Advertisement
Advertisement
Advertisement

Oncolytics Biotech Inc. (ONC.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
1.6600-0.0100 (-0.60%)
At close: 03:59PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • L
    L
    The outlook is that a Big Pharma company would be seeking to obtain an accelerated approval on ONCY'S aggregated clinical trial results obtained from the IND-213, AWARE-1 and BRACELET-1 Phase 2 clinical trials.. Once an accelerated marketing approval is granted to pelareorep and the drug is conditionally on the market ONCY's acquirer will add in a Phase 4 confirmatory trial.to obtain final approval thus concluding the overall application and approval process.
  • D
    Dan
    Trying to buy an other 10k shares. It Will bring me at 100k shares. My friend has 500k shares... won’t be able to catch him!
  • M
    May
    Given all the combination studies, when are Phase three results to be reported?

    Seems likely a big Pharma would buy ONCY to create a combo that effectively extends the patent on the resulting drug combo.
  • L
    L
    ONCY's pelareorep + CAR-T therapy as explained by Mayo Clinic

    "Researchers at Mayo Clinic's Center for Individualized Medicine have devised an immunotherapy technique that combines chimeric antigen receptor-T cell therapy, or CAR-T cell therapy, with a cancer-killing virus to more effectively target and treat solid cancer tumors."

    "The study suggests CAR-T cells can deliver the oncolytic virus to the tumor. Then the virus can infiltrate tumor cells, replicate to bust the cells open, and stimulate a potent immune response."

    "This approach allows the tumor to be killed by the virus as well as by the CAR-T cells," explains Richard Vile, Ph.D., co-leader of the Gene and Virus Therapy Program within Mayo Clinic Cancer Center and the Richard M. Schulze Family Foundation Professor. "In addition, when the virus is delivered, it turns the tumor into a very inflammatory environment, which the patient's own immune system then sees and starts to attack."

    "By putting the virus onto the CAR-T, we activate them against both the virus and the tumor, and they acquire immunological memory," Dr. Vile says. "This allows us to give a boost with the virus at a later time point, which in turn makes the CAR-T cells wake up again and undergo additional rounds of killing the tumor."

    They found that the combination therapy led to high cure rates in tumors in multiple sites without causing significant toxicity. They also found it resulted in apparent protection in the cured mice against tumor recurrence.

    "Clinically, delivering the therapy systemically is a potential advantage because you could possibly treat patients with metastatic disease without having to inject each tumor," Dr. Vile explains.
  • a
    armedescapade
    For a little change of locality and....outlook. L will love it. The heart of America, no? Scary, eh? L?

    https://www.youtube.com/watch?v=kyFnLqJx-uU
    Haaaaaaa......................
    Kid Rock - We The People (Official Video)
    www.youtube.com
  • c
    canadafan
    most recent director bio:
    Mr. Rigby added, "The opportunity to join Oncolytics at this crucial stage in the Company's evolution and help forge the Company forward to treat these terrible cancers is compelling. Extensive clinical data have demonstrated pelareorep's ability to provide a statistically significant survival benefit in breast cancer, its potential to synergize with checkpoint inhibition and drive objective responses in pancreatic cancer, as well as how its multifaceted mechanism of action positions it to enhance the efficacy of additional drug classes across various indications. Upcoming data readouts in breast and pancreatic cancer will provide valuable opportunities to accelerate pelareorep's path towards registration in these indications. I am keen to lend my insights to company management and the Board as they work towards these potential catalysts and prepare for anticipated growth."

    Mr. Rigby joins Oncolytics' Board with over three decades of experience in the pharmaceutical and biotechnology industries. He is currently the Group Chief Executive Officer (CEO) of Revolo Biotherapeutics, where he leads a team focused on the development of therapies for autoimmune and allergic diseases. Previously, he was the CEO of SteadyMed Ltd., which he led through a NASDAQ listing and sale to United Therapeutics Corporation. Prior to his time at SteadyMed, Mr. Rigby co-founded Zogenix, Inc., a CNS-focused specialty pharmaceutical company that was acquired by UCB earlier this year in a transaction valued at up to approximately U.S. $1.9 billion. Before co-founding Zogenix, Mr. Rigby held roles of increasing responsibility in commercial and business development functions at large pharmaceutical companies such as Merck, Bristol Myers Squibb, and Profile Therapeutics (now Phillips Medical). In addition to his Oncolytics appointment, Mr. Rigby is also a member of the Revolo Biotherapeutics and ImmunoMolecular Therapeutics Boards of Directors and the Chairman of BIOS, a Nasdaq-listed biotech acquisition company. He holds a B.S. with Honors in Biological Sciences from Sheffield University, UK, and an M.B.A. from Portsmouth University, UK.......
    He is also Chiar of a Nasdaq listed company:BioPlusa aquistions. Tier only reason for exiting is assting in buy-outs & acquisitions, of junior Pharma,
    Bullish
  • U
    Uber
    Who was it who said the next appointment to the BOD will be a real estate agent? I think you're on to something whoever posted that. It's starting to get cold in Calgary boys and girls, and you know what that means. Mrs. Matt has been wintering in San Diego with your (ahem), totally dedicated and hardworking CEO for what, 5-6 years now? Yeah, the proximity to the epicenter of all things biotech in Southern California is certainly mission critical to getting Pela commercialized (wink, wink), but it's getting old and there are so many new places to see. I'm thinking a new, 3rd office in say, Tuscany might fit the bill. Or maybe Barcelona. What?!! You don't think it's a wise use of your cash? Well just LOOK at how much progress Matt has made on REO/Pela since he opened his California offices. He should make at least as much progress advancing Pela through trials and to market in Florence. Yep, don't be surprised when Ben Caballero is the next appointee to Matt's board.
  • L
    L
    In the recently released ReoGlio study data that treated newly diagnosed glioblastoma multiforma (GBM) patients with pelareorep in combination with GM-CSF and standard chemoradiotherapy "the 24-month survival estimate for all patients was 25.0%, 16.7% for dose level 1 and 33.3% for dose level 2."

    By comparison in a 2018 retrospective GBM study in a patient population of seventy-seven patients who were treated by multimodality therapy such as surgery plus post-operative radiotherapy (PORT), post-operative Temozolomide (TMZ) concurrent with radiotherapy (CCRT), post-operative CCRT with adjuvant TMZ the overall survival 24 month survival for all patients was 21.3%.

    In this ONCY ReoGlio study of newly diagnosed GBM patients, none of the 15 ReoGlio patients underwent devastating and debilitating surgery nor did they require follow-up chemoradiotherapy, whereas in the 2018 retrospective study of 77 patients, all patients underwent surgery, as well as 2 courses of chemoradiotherapy (TMZ+ radiotherapy post operatively).
  • c
    canadafan
    Food for thought.
    With oncology meds ( chemo, IV, various other types), becoming a massive growth industry.
    Assuming the remaining/ additional patients enrolled into Goblet ( pancreatic cancer), show similar results as the run-in trial?
    Pelareorep alongside Roche, could become a blockbuster drug combo.
    With an 8 week & 16 week window, that aligns perfectly with managements prediction of a strong announcement near end of year.
    Since panc cancer has next to zero treatments. & 5 year survival of less than 5%.
    A 48% tumour shrinkage as shown in the run- in is amazing.
    Please don’t take my word.
    Go to onc web site.
    There is a peer reviewed publication. As well, listen to recent CC,
    Very positive anticipation of year end updates.
    Bullish
  • G
    Gregory
    Canadafan, My wife was diagnosed with Stage 4 colon cancer with metestaic tumors in her liver lung and brain. In 2017. Drs told me she had 6 months to live. She was 36 years old and was super strong. Drs asked her if she wanted to try something new, immunotherapy (opdivo). She had nothing to loose, so she agreed......6 weeks later her tumors, all of them, started to shrink. After a year she is NED.....No evidence of disease. I am so greatful for the miracle of immunotherapy, it saved not only her life but mine, as well as our children. If Pela can increase the amount of patients that get a positive result like my wife's, its truly a miracle and I am all in.
  • D
    Dan
    After 25 years, show me the money is the last intelligent post from Tam Tam! Wow!
  • L
    L
    The Era of Precision Medicine is upon us.

    “The next era is about outcomes and pharma is at a moment of truth in company strategies around focus, innovation and in particular, how they can affect patient outcomes beyond the medicine. For example, in the past, we spent time helping the doctor find the patient, and now we have to help the patient find the right doctor and the right care.”

    [ ONCY has positioned pelareorep for this new era.

    ONCY's pelareorep + immune checkpoint inhibitors (ICI), complimented by the predictive diagnostic biomarkers being developed for pelareorep, is demonstrating that this IO treatment combination delivered through optimal route of systemic delivery (IV)], is able to be given to the right patient, at the right time, in the right disease, resulting in synergistic treatment effectiveness and durability of treatment.]
  • D
    Dan
    We have to stop to talk about of the past performances or none performances! ONCY is in a phase of transformation and will reward shareholders that can see the bright futur. Have your shares before the fireworks 💥 🔥. Have a great weekend,
  • c
    canadafan
    The most recently added director, Mr. Rigby, comes from a vast background of business development & mergers.
    Notably is is ceo of Nasdaq listed BIOS,
    That company’s only reason for existing is mergers & acquisitions of bio/ medical companies.
    So; two new directors, within 5 months.
    Both with massive large pharma contacts.
    Both with buy-out experience.
    A clear & deliberate movement away from medical oversight to business development oversight.
    I recommend, you look up, the biosu on Nasdaq
    Interesting.
    That, in one of Mr. Rigby’s many contacts.
    They now have a majority of BOD from business development background.
    Assuming a board vote ….they would/ could move the needle.
    All, good signs for end of year..stuff.
    The press release is very clear. They are going after BOTH, the most recent pancreatic cancer with Roche & MBc cancer with Pfizer.
    Having a strong B.D. Board will certainly move that.
  • B
    Branko
    The appointment of Rigby is good news long term but suggests that we're not near a deal around the corner...think about it, new board member joins and company gets sold a few months later. unlikely
  • c
    canadafan
    We have certainly seen better trading days. Then again that applies, broad market last few days.
    Bullish
  • c
    canadafan
    d like to add yet another, seldom discussed side on ONC Pelareorep.
    Point: There are a handful of trials we have named & talked about repeatedly.
    How about the 100 or so people ( patients in trials), who wake up every day with hope.
    hope of progress from Pela & other combo treatments.
    Yet, perhaps at bed time sleep in fear of treatment failure.
    Do they own shares in Onc? Maybe, maybe not.
    Their “lottery” is not measured in SP, Market cap, daily trading volume.
    They no doubt along with their families hope & pray for success.
    THAT is an investment.
    let that sink in a while …
  • K
    Kenny
    Dan, I only have about 50K shares..... which is 100 times more than we would expect Tam from planet Pluto to have. She keeps deleting my posts because I keep exposing her for the dope she is. Why oh why would anyone invest in a spec. stock only to daily bash it publicly on a message board. Only one reason. Well she does keep mentioning mental hospitals when ever she responds to my intelligent posts. (( and please that is not any veiled attempt to make me seem superior to anyone .... well other than Tam the magnificent ((dope)) but I digress .... ) She has invested heavily she claims but yet she only trashes her own investment... Anyone who pays attention to this alien should be put back on that crashed vessel that landed in area 51 and be transported back to youranus ahhhh I mean Uranus.. or what ever she wants to delete of mine.... ignorant #$%$!!!
  • D
    Dan
    Mr Parsons is a good addition too. GL
  • a
    armedescapade
    Tam, institutional investors usually have high minimum guidelines, some, like retail funds can peck at few thousand shares at a time, but that's within basket of securities (different companies). spreading the risk. For us increased interest by Pharma is what counts, if you want to time a possible uptick in share price. Leaked news (and that's all the time with money that the practice involves) will prompt institutions and big private funds to pile up in an emerging stock. And ONCY does fit that (emerging, but not quite). ONCY is like a baby stuck in the birth canal for 25 yrs. Yikes. Can you imagine the scene...? Dr, Matt sitting in a chair beside it, smoking cigar and sipping Napoleon cognac trying to dull the senses from the stink emanating from the mess. Picturesque enough? :)))
    Man, the camera in my front lobe is working overtime. So different for our pump brigade. The things they imagine, and reality are entirely dissociable. The question is: is it incidental or deliberate?
    It is known that what we imagine hearing can change what we actually see, and what we imagine seeing can change what we actually hear. Can you imagine the cacophony in Canada's head. I don't even mention L, he is beyond measurement.
    Just some thoughts to go with coffee. And for me to pontificate.:))))
    Beautiful day. Time to go play outside.
Advertisement
Advertisement